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Recent physiological and pharmacological studies
have indicated the potential importance of tryp-
tase, the major protein component in mast cells,
in in ammatory diseases (especially asthma).
Being released at in ammatory sites after the
activation of mast cells, tryptase is capable of
causing bronchohyperresponsiveness and in l-
tration of eosinophils, neutrophils, etc. in animal
airways. The mechanisms by which tryptase
causes bronchoconstriction involve probably the
potentiation of other chemical mediators such as
histamine, production of bradykinin via the hy-
drolysis of kininogen, and cleavage of the
bronchodilating peptides VIP (vasoactive intest-
inal peptide) and PHM (peptide histidine-methio-
nine). Tryptase has also been found to be a potent
mitogen in vitro for airway smooth muscle cells
and epithelial cells, implying its role in the
hyperplasia of the asthmatic airways. The experi-
mental data providing evidence for the above
roles of tryptase are summarized in the present
review, as well as the effects of tryptase inhibition
in animal asthma models. The potential strategies
for the development of anti-asthmatic agents
based on the inhibition of tryptase are discussed.
Key words: H1-antagonists, Asthma, Histamine, Mast
cells, Tryptase, Tryptase inhibitors
Introduction
Mast cells have long been implicated in the
pathogenesis of asthma, particularly in the acute
response occurring immediately after exposure
to allergen. Binding of allergen molecules to IgE
antibodies on mast cells and the subsequent
cross-linking directly or indirectly activate var-
ious enzymes in the cell membrane. Cascades
involving tyrosine kinase enzymes, phospho-
lipase C, protein kinase C and an inux of
calcium ions induce chemical-laden granules to
release their preformed contents. These cas-
cades also appear to promote the synthesis and
extrusion of lipid chemicals such as prosta-
glandins and leukotrienes. The various chemi-
cals emitted by active mast cells may induce
many allergic symptoms as well as the migration
of eosinophils, basophils and other cells into
the tissue so as to cause inammation.
Histamine is perhaps the most infamous of
those preformed chemical mediators released
by mast cells, and antihistamines have thus
attracted a great deal of research attention.1
Much less is known, however, about the serine
proteases, tryptase and chymase that are also
preformed in the secretory granules of mast
cells. Together these enzymes represent the
major protein components of the mast cell, up
to 20±25% of the total protein content.2 Tryp-
tase is particularly notable for its abundance in
mast cells. It resides in the secretory granules of
all mast cells from the time granules  rst begin
to form,3 whereas others dwell in the granules
of a subpopulation of mast cells. Those mast
cells with tryptase only are called MCT cells,
and those with all of the enzymes are called
MCTC cells.4 MCT and MCTC cells have quite
different sets of distribution in human tissues.
Whereas MCT cells are the major component in
alveolar tissue and small intestine mucosa, mast
cells in skin and ocular conjuctiva are mostly
MCTC cells. At present no physiological or
pathological function has been denitively as-
signed to mast cell tryptase although it has been
used as a speci c marker of mast cell
activation.5 The abundance of the enzyme in
mast cells, in conjunction with some of its
recently observed biological activities, warrants
further research on the potential role of tryp-
tase in allergy and inammation. In this review,
the current knowledge of molecular properties
and biological activities of tryptase, specially
those related to asthma, will be presented
together with the effect of tryptase inhibition in
animal asthma models.
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Biochemistry of Mast Cell
Tryptase
Molecular properties of tryptase
Mast cell tryptase (EC 3.4.21.59) is a trypsin-like
serine proteinase with 40% sequence identity
with trypsin and only 20 or 21 additional
residues. However unlike trypsin, tryptase only
cleaves a limited number of proteins and is not
inhibited by endogenous proteinase inhibitors
such as a1-proteinase inhibitors and secretory
leukocyte protease inhibitors.6,7 Several differ-
ent sequences for human tryptase have been
reported and a few examples are listed in Table
1. They are highly conserved ( . 70%homology)
and all form homogenous tetramers of a total
molecular mass of 110±150 kDa, with each
subunit of 31 to 38 kDa (Table 1). A reduction
in molecular mass of tryptase subunits of 2000±
4000 Da after treatment with endoglycosidase
indicates that carbohydrates are present on each
subunit.10 Inside mast cell granules and after
secretion, tryptase is stabilized in its active
tetrameric form by binding to heparin, via ionic
interactions.8 When free in solution, tryptase
subunits irreversibly dissociate from one an-
other into inactive monomers, without any
evidence for autodegradation. Substantial con-
formational changes occur during this process,
as evidenced by circular dichroic spectral shifts
and by distinct epitopes being detected on the
active tetramer and inactive monomers.12
3D structures of tryptase
The three-dimensional structures of tryptase
have been predicted by molecular modelling
based on the crystal structure of bovine
trypsin.13 The models show two large insertions
to lie on either side of the active-site cleft,
suggesting an explanation for the limited activ-
ity of tryptases on protein substrates and the
lack of inhibition by natural inhibitors. A group
of conserved Trp residues and a unique proline-
rich region make two surface hydrophobic
patches that may account for the formation of
tetramers and/or inhibition with increasing salt.
Although they contain no consensus heparin-
binding sequence, the tryptases have 10±13
more His residues than trypsin, and these are
positioned on the surface of the model. In
addition, clustering of Arg and Lys residues may
also contribute to heparin binding. Putative
Asn-linked glycosylation sites are found on the
opposite side of the model from the active site.
The model provides structural explanations for
some of the unusual characteristics of the
tryptases and a rational basis for future experi-
ments, such as site-directed mutagenesis.
Recently ve different tryptase cDNA mole-
cules have been cloned and sequenced, two (a
and b) from human lung mast cell cDNA library
and three (I, II, III) from human skin mast cell
library.14 Two genes for human tryptase have
been localized to chromosome 16.15,16 One
corresponds to a-tryptase and tryptase III, and
the other to b-tryptase, tryptase I, and tryptase
II. The amino acid sequence of a-tryptase
contains 24 amino acid differences and a single
amino acid deletion compared to b-tryptase
sequence. These two isoforms of human lung
tryptase were reported to have different cleav-
age rates for peptide substrates, e.g. VIP.17
Besides human tryptases, animal tryptases
have also been puri ed. These include guinea-
pig lung tryptase,18 bovine tryptase,19 dog
tryptase,20 rat tryptase,21 murine tryptase,22 and
gerbil tryptase.23
Enzymatic assays of tryptase activity
Tryptase activity is typically measured by the
rate of cleavage of small synthetic ester or
peptide substrates with Arg or Lys in the C-
terminal position. An example is given as
follows.14 To a solution of 1 mMtosyl-L-arginine
methyl ester (TAME) in 1 ml 0.04 M Tris-HCl
buffer (pH8.1) containing 0.15 MNaCl is added
tryptase at either room temperature or at 378 C.
The molar extinction coefcient for the change
in absorbance at 247 nm equals 540. The
concentration of TAME can be conrmed by
measuring the absorbance at 247 nm after
complete cleavage of the substrate by excess
trypsin. Puri ed tryptase typically exhibits a
speci c activity of 100±120 U/mg.
A variety of tripeptide derivatives of p-nitro-
anilide are also used to assay tryptase.24 The
Table 1. Molecular properties of human tryptase from difference sources
Source Molecular weight
(heparin)
No. of subunit Subunit molecular
weight (kDa)
Glycosylation Reference
Lung 130 (+) 4 31±33/35±37 + 2, 6, 8
Skin 120 (+) 4 34/38 + 9
Pituitary 110 (?) 4 34/36 + 10
HMC-1 150 (+) 4 32/35 + 11
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change in absorbance of p-nitroaniline at
405 nm is used as a indicator for the cleavage.
Mast Cell Tryptase in Asthma
Elevated levels of tryptase in asthma
Tryptase resides in secretory granules of human
mast cells and is released together with histam-
ine upon the actions of certain stimuli. Hista-
mine, once released, is free to diffuse rapidly
through tissue into the blood stream or onto
tissue surfaces, whereas tryptase diffuses more
slowly, presumably because of its macromolecu-
lar complex. During bee-sting induced anaphy-
laxis, tryptase levels in the blood stream are
maximal at 60±120 min, whereas those of
histamine are maximal at 5 min.25 Tryptase
levels then decline with a half-life of 1.5±2.5 h,
and histamine with a half-life of only a few
minutes. In skin chamber uid26 and surface of
airway,27 the analogous but shorter delay of
tryptase appearance in comparison with histam-
ine were also reported. Because of the asso-
ciation of mast cell activation with many
allergic diseases, it is not surprising to observe
elevated levels of tryptase in these allergic
conditions. Several studies have shown that
tryptase levels in asthmatic patients are signi -
cantly higher than those in normal subjects.27
Thus allergen challenge in atopic subjects
caused an elevation in tryptase levels in
bronchoalveolar lavage uid above baseline
values both in asthmatic and nonasthmatic
subjects, but not in nonatopic groups. In
aspirin-sensitive asthmatics, the increase in nasal
symptoms after aspirin ingestion was found to
correlate with the increase in nasal tryptase
levels (mean maximal increase: 3·5 26 ng/ml,
versus placebo: 0·1 0·2 ng/ml, P , 0·05) as
well as the increase of nasal histamine and
leukotriene levels.28 Interestingly treatment with
zileuton, a 5-LO inhibitor, blocked the increase
in nasal symptoms after aspirin ingestion, and
it also blocked the rise in nasal tryptase
(P = 0·011) and nasal leukotriene (P , 0·05)
levels, but not nasal histamine. Tryptase is also
implicated in adenosine (AMP)-induced bron-
choconstriction.29 Immediately after instillation
of AMP directly into an airway segment of eight
asthmatic subjects, a prompt reduction in air-
way caliber was observed in parallel with a
signicant rise in PGD2, histamine, and tryptase
levels in the lavage uid. After AMP challenge,
the median (range) concentration for tryptase
was changed from 0.30 to 0.54 ng/ml
(P = 0·013). These results indicate that adeno-
sine-induced responses may be initiated by the
acute release of mast-cell-derived mediators,
including PGD2, histamine, and tryptase.
The presence of higher tryptase (10 7 U/ l
vs. 0·9 0·9 U/ l, P = 0·0001) levels was also
reported in patients with acute severe asthma
than in those with cystic  brosis.30
Biological activities of tryptase
relevant to asthma
Although the biological activities of tryptase
have not been clearly elucidated, a number of
actions of tryptase potentially relevant to asth-
ma have been reported (Fig. 1).
Tryptase appears to potentiate the action of
histamine and other contracting agonists so that
to cause smooth muscle hyperresponsiveness in
asthma.31 Preincubation of dog tracheal smooth
muscle with tryptase in vitro caused a marked
leftward shift of the histamine concentration±
response curve with the ED50 of histamine
decreasing from 19 mM to 2 mM (Fig. 2a). The
maximum tension induced by histamine after
the treatment with tryptase was increased from
110 to 170 g/ g tissue weight, but tryptase alone
did not increase resting tension. These aug-
mented contractile responses to histamine were
dependent on the concentration of tryptase
added (Fig. 2b), and they were reversed by a
histamine H1 antagonist or prevented by a
tryptase inhibitor.
Similar effects of tryptase to the contractile
potency of serotonin and KCl, but not acetyl-
choline, were also observed, suggesting that the
enzyme exerts its effects at a point in the
stimulus-contraction pathway shared by the
three chemically distinct agonists. Because the
smooth muscle effects of histamine, serotonin
and KCl depend on the movement of external
Ca2+ into the cell, and because Ca2+ channel
blockers (nifedipine and verapamil) abolish
MAST CELL tryptase
histamine
KININOGEN
BRADYKININ
BRONCHO-
CONSTRICTION
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PHM
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FIG. 1. Pathogenetic activities of tryptase in asthma. Tryp-
tase augments the contractile potency of other chemical
mediators, e.g. histamine; hydrolyses kininogen to produce
bradykinin, and cleaves the bronchodilators vasoactive
intestinal peptide (VIP) and peptide histidine-methionine
(PHM). (See text for details.)
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contractions induced by the combination of
tryptase and histamine, it was speculated that
tryptase might affect airway smooth muscle
responsiveness by modifying Ca2+ channels.
This hypothesis is supported by the failure of
tryptase to augment the contractions produced
by acetylcholine, an agonist whose smooth
muscle effects are mediated by a mechanism
independent of voltage-dependent Ca2+ chan-
nels. Tryptase could affect the channel itself or
cleave a regulatory protein on the cell surface.
Recently in a study of 17 children with mild
to moderately severe chronic asthma,32 bron-
chial responsiveness to histamine was found to
correlate highly with mast cell tryptase levels
(r = - 0·714, P , 0·005), further supporting the
notion that tryptase possibly induced upregula-
tion of bronchial smooth muscle tone.
Mast cells have long been suggested to play a
role in the modulation of neuropeptides be-
cause of its close anatomic association with
peptidergic nerves. It was reported that human
tryptase rapidly hydrolysed vasoactive intestinal
peptide (VIP) and peptide histidine-methionine
(PHM), but not the tachykinin substance P.33
VIP and PHM are potent bronchodilating pep-
tides co-transcribed and co-expressed in airway
motor neurones. Degradation of these broncho-
dilating peptides in connection with the un-
changed level of the bronchoconstricting
substance P may contribute to the increase in
bronchial responsiveness associated with asth-
ma. In vitro animal studies have indeed showed
that tryptase reverse VIP-induced airway
smooth muscle relaxation of guinea-pig lung34
and dog trachea.35
Tryptase has also been reported to hydrolyse
kininogen to produce bradykinin,36,37 a non-
apeptide which is one of the most potent
vasodilators and increases vascular permeability.
It is known that kininogen is consumed during
anaphylactic reactions in man, and conse-
quently bradykinin and lysylbradykinin are gen-
erated.38 Administration of bradykinin to the
lower airways induces bronchoconstriction in
asthmatics. Under optimal conditions (pH 5.5),
human tryptase produced bradykinin from kini-
nogen at a rate of 10±12 mg bradykinin/h/mg,
but only 2 mg bradykinin/h/mg at pH 7.2.36
Since the optimal pH is within the range of
mast cell granule, it is also possible that this
activity of tryptase is retained to another intra-
cellular substrate. Tryptase additionally cleaves
C3 and generates the anaphylatoxin, C3a, a
potent bronchospastic agent.14
Tryptase has further been shown to be a
potent mitogen for airway smooth muscle
cells39,40 and epithelial cells.41 At a concentra-
tion of 4 nM, tryptase increased dog tracheal
smooth muscle cell numbers 2.1- and 2.8-fold
above controls after 2 or 4 days of incubation,
respectively.39 These increases were approxi-
mately the same as those induced by platelet-
derived growth factor (50 ng/ml) or 10% calf
serum. With respect to potency, tryptase caused
concentration-dependent increases in bromo-
deoxyuridine (BrdU) uptake, as detected in an
enzyme-linked immunosorbent assay or by
counting BrdU-labelled nuclei, with an EC50 of
2 nM. The mitogenic effect of tryptase for
airway smooth muscle cells could be respons-
ible for the hyperplasia in the airways of
asthmatic patients and may contribute to the
development of the bronchial hyperresponsive-
ness that occurs in these patients.
Tryptase was also found to stimulate DNA
synthesis in the human epithelial cells in
vitro .41 Maximal growth of the human epithelial
cell line H292 was observed after 24 h using
25 mU/ml of tryptase, a concentration that is
likely to be achieved in vivo . Inhibitors of
tryptase activity, including leupeptin and benza-
midine hydrochloride, signicantly decreased
FIG. 2. (A) Effect of tryptase (90 ng/ml) on concentration±
response curve of histamine in dog bronchial smooth
muscle; (B) concentration-dependency of tryptase on hista-
mine (1 mM) induced contraction in dog bronchial rings
(made according to Sekizawa et al.
31
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tryptase-induced stimulation of DNA synthesis,
indicating the requirement for an active cataly-
tic site. Tryptase also stimulated a catalytic site-
dependent release of IL-8 from epithelial cells
after 24 h, and this was associated with upregu-
lation of ICAM-1 expression, as revealed by
FACS analysis. Tryptase may thus play a critical
role in epithelial repair and in the recruitment
of granulocytes following mast cell activation.
Indeed, it has recently been shown that tryptase
acted as a chemoattractant for eosinophils and
neutrophils, and could activate eosinophils
and mast cells.42 Since eosinophils are likely
the most important in ammatory cells in asth-
ma, the recruitment of eosinophils may account
for the potential inammatory activities of
tryptase.
Inhibitors of Mast Cell Tryptase
as Anti-asthmatic Agents
Inhibition of tryptase release
Tryptase is released together with histamine
from mast cells, and therefore those mast cell
membrane stabilizers, which inhibit the release
of histamine, should also be able to inhibit the
release of tryptase. Indeed oxatomide, a histam-
ine H1 receptor antagonist known to inhibit
histamine release from mast cells, is also effect-
ive in the inhibition of tryptase release.43
Preincubation (15 min, 378 C) of HLMC and
HSMC cells with oxatomide (10 - 7 ±10 - 5 M)
before anti-IgE challenge concentration-de-
pendently (10±40%) inhibited the immunologic
release of histamine, tryptase and LTC4, indi-
cating that oxatomide exerts anti-inammatory
activities by inhibiting the release of preformed
and de novo synthesized mediators from human
mast cells and basophils.
Loratadine, another histamine H1 receptor
antagonist relatively effective in the treatment
of bronchial asthma, was shown to inhibit the
exudation of a2-macroglobulin and to reduce
tryptase levels.44 The reduction of tryptase
levels in nasal lavage uid by loratadine corre-
lated with its reduction of nasal symptoms and
obstruction in allergic rhinitis. The inhibitory
effects of loratadine on nasal lavage uid levels
of a2-macroglobulin suggest that histamine,
through effects on microvascular H1-receptors,
mediates allergen-induced exudation of bulk
plasma in acute allergic rhinitis. The reduced
lavage uid levels of tryptase suggest either that
loratadine directly attenuates mast cell release
activity or that loratadine, through inhibition of
the exudation process, simply attenuates lumi-
nal entry of tryptase.
Inhibition of tryptase effectors
As discussed earlier, tryptase exerts its biologi-
cal activity via a number of effectors, e.g.
histamine, bradykinin, etc. Therefore, inhibition
of tryptase effectors would also in principle
limit the effects of tryptase. It has been shown
that inhaled tryptase (100 and 500 ng in 2 ml
H2O solution) increased pulmonary ow resist-
ance (RL) (mean SE) by 33 12 and
122 8% (P , 0·05) over baseline.45 The re-
sponse was reproducible upon repeat chal-
lenges. The response to tryptase was blocked
by pretreating the sheep intravenously with the
histamine H1 antagonist chlorpheniramine
(2 mg/kg), in which RL increased only 5 4
and 7 6%after 700 and 500 ng tryptase.45
It has also been demonstrated that intra-
dermal injection of tryptase-heparin complex (1
or 10 ng tryptase + 3 U heparin) in allergic
sheep caused immediate cutaneous reaction
(ICR) 50±82% relative to that caused by his-
tamine (5%wt/ vol).46 This response is speci c
because tryptase and heparin alone caused only
minimal ICR, ruling out the possibility that the
animals had become sensitized to the tryptase
or some other unknown proteins. Furthermore
a mixture of heat-inactivated tryptase and hep-
arin also caused no ICR. In addition to the
blockade by tryptase inhibitors, the ICR caused
by tryptase ±heparin complex can also be
blocked by a combination of histamine H1 and
H2 antagonists [chlorpheniramine (2 mg/kg) +
metiamide (3 mg/kg)], indicating that tryptase
acts via histamine.46 One possible mechanism
may be that tryptase regulates mediator release
from mast cells.42
Inhibition of tryptase activity
The most direct proof of tryptase’s role in
asthma comes from the selective inhibition of
tryptase itself. APC 366 (Fig. 3), a selective
tryptase inhibitor discovered by Arris Pharma-
ceutical Corporation, has been shown to block
antigen-induced bronchoconstriction and in-
ammatory responses in allergic sheep.45,47
APC 366 (apparent Ki = 330 nM) is a selective
OH
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FIG. 3. Structures of tryptase inhibitors APC 366 and
BABIM.
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tryptase inhibitor without signicant activity
against other proteases. Acute treatment (0.5 h
before challenge) with APC 366 (9 mg/3 ml
H2O, aerosol) did not affect the maximum
bronchoconstriction of allergic sheep immedi-
ately after challenge but did cause a more rapid
reversal of the increase in speci c lung resist-
ance. This response was associated with a
signicant inhibition of tryptic activity in the
bronchoalveolar lavage uid. Twenty-four hours
after challenge, APC 366 completely blocked
the antigen-induced airway hyperresponsiveness
to inhaled carbachol observed in the control
experiments, but did not block histamine-
induced bronchoconstriction.
When given 18 mg twice daily for 3 days and
once 18 mg again 30 min before antigen chal-
lenge, APC 366 markedly inhibited the immedi-
ate response as compared with the acute
treatment. The marked inhibition of the im-
mediate bronchial response to antigen under
this prophylactic treatment could indicate that
tryptase is not only released in conjunction
with other preformed mast cell mediators but
might also act to modulate the release and/or
effectiveness of the other spasmogens. APC 366
also showed anti-inammatory actions by block-
ing antigen-induced eosinophil accumulation in
bronchoalveolar lavage uid (treatment: 1.6 to
5.1 eosinophils/mm2 vs. control: 1.2 to 17.2
eosinophils/mm2, P , 0·05), as well as the
increase of albumin levels in bronchoalveolar
lavage uid. These results further support the
suggestion that tryptase may act as a chemo-
attractant to eosinophils42 and hydrolyse kin-
inogen to bradykinin so to increase vascular
permeability.36,37
Similar anti-asthmatic activity has been
demonstrated with BABIM (Fig. 3), another
potent and reversible inhibitor of tryptase
(Ki = 1·8 nM).47 A limited structure-activity rela-
tionship study showed that both amidine
groups of BABIM are important for potent
tryptase inhibitory activity, and at least one of
the amidine groups should be unsubstituted
since cyclization of both amidine groups into
imidazoline rings afforded a compound without
activity.48 BABIM was shown to block comple-
tely the reversal of VIP-induced relaxation of
isolated trachea by dog tryptase.48
General Remarks
Because tryptase is unique to mast cells
(although small amount of tryptase have been
detected in basophils), inhibition of tryptase
offers potential selectivity towards the condi-
tions where mast cells are predominant. There
is compelling evidence to suggest the important
role of mast cells in allergic asthma. The limited
success of anti-asthmatic agents related to ac-
tions on mast cells, e.g. antihistamines and
DSCG, may be attributed to the low airway
tissue concentrations achievable with systema-
tic application of these agents. It has been
reported that cetirizine, a non-sedating H1
antagonist, when given orally 10 mg twice daily
for 1 week, failed to inhibit exercise induced
bronchoconstriction (maximum falls in FEV1
28% and 27% of baseline), but when given by
inhalation (1 ml, 5 and 10 mg/ml) cetirizine
markedly reduced the fall in FEV1 after exercise
by 15.2%, and 10.2% of baseline, respectively,
compared with 23.7% after placebo.49 Tryptase
inhibitors may have potentially a similar fate
when applied in the treatment of asthma. How-
ever, the inammatory actions of tryptase, e.g.
recruitment of eosinophil, synthesis of bradyki-
nin, etc., may afford tryptase inhibitors addi-
tional anti-inammatory pro les as seen in the
animal studies of APC 366. These anti-inamma-
tory activities coupled with symptomatic reliev-
ing effects of tryptase inhibitors should warrant
them as promising candidates for further re-
search and development. Recent phase II clin-
ical trials results of APC 366 have showed that
the agent at doses of 2.5 or 5.0 mg three times a
day for a total of 13 doses improved both the
late and the hyperresponsive phase of the
asthmatic reaction to allergen, compared to
baseline. The full scienti c report of this study
and many more advanced clinical trials is
eagerly awaited. By then, the anti-asthmatic
advantage of tryptase inhibitors would have
been more evident.
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